
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a promising investment option due to their impressive targeted drug discovery platform, as well as their strong pipeline of potential treatments for precision oncology and genetic diseases. Their recent financing and increased possibilities of FDA approval for their lead drug, zovegalisib, also provide positive indications for future success. Despite the inherent risks in drug development and potential competition, Relay Therapeutics has shown strong efficacy and safety results in clinical trials, increasing their chances of success in the market.
Bears say
Relay Therapeutics is a clinical-stage precision medicine company that focuses on developing therapies for precision oncology and genetic diseases. Despite promising early data for its drug, zovegalisib, analysts are concerned about the company's financials, including the high costs of systemic therapies and potential competition from other companies. Additionally, the limited efficacy data and small sample size may make it difficult for Relay to gain regulatory approval, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares